(Q33333726)

25 July 2017

Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma (English)

1 reference

transitional cell carcinoma

25 July 2017

phase II clinical trial

0 references

1 reference

Dodd PM

1

1 reference

25 July 2017

McCaffrey JA

2

1 reference

25 July 2017

Mazumdar M

3

1 reference

25 July 2017

Icasiano E

4

1 reference

25 July 2017

Higgins G

5

1 reference

25 July 2017

Herr H

6

1 reference

25 July 2017

Bajorin DF

7

1 reference

25 July 2017

1 August 2000

1 reference

Investigational New Drugs

25 July 2017

1 reference

25 July 2017

18

1 reference

25 July 2017

247-251

1 reference

25 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006477823378

25 July 2017

0 references

cites work

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

12 December 2020

Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes

1 reference

12 December 2020

The Norton-Simon hypothesis revisited

1 reference

12 December 2020

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

12 December 2020

Chemotherapy for urothelial tract malignancies: breaking the deadlock

1 reference

12 December 2020

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

12 December 2020

Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B

1 reference

12 December 2020

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial

1 reference

12 December 2020

Estimating with confidence

1 reference

12 December 2020

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.

1 reference

12 December 2020

Conceptual basis for advances in the systemic drug therapy of breast cancer.

1 reference

12 December 2020

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

12 December 2020

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

12 December 2020

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

12 December 2020

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

12 December 2020

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934)

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006477823378

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference